Inclusion Criteria

- INCLUSION CRITERIA:

Recipient Criteria:

Diagnosed with one of the following hematological conditions:

- Chronic myelogenous leukemia (CML): chronic phase who have failed treatment with
imatinib, have intolerance to imatinib, or who did not receive imatinib at
therapeutic doses within the first 12 months from diagnosis; accelerated phase or
blast transformation.

- Acute B-lymphoblastic leukemia (B-ALL): any of these categories: B-ALL in first
remission with high-risk features (presenting leukocyte count greater than 100,000/cu
mm, Karyotypes t9; 22, t4, t19, t11, biphenotypic leukemia), all second or subsequent
remissions, primary induction failure, partially responding or untreated relapse.

- Acute myelogenous leukemia (AML): AML in first remission - except AML with good risk
karyotypes: AML M3 (t15; 17), AML M4Eo (inv 16), AML t (8; 21). All AML in second or
subsequent remission, primary induction failure and resistant relapse.

- Myelodysplastic syndromes (MDS): any of these categories - refractory anemia with
transfusion dependence, refractory anemia with excess of blasts, transformation to
acute leukemia, chronic myelomonocytic leukemia, atypical MDS/myeloproliferative
syndromes.

- Myeloproliferative disorders including atypical (Ph negative) chronic myeloid and
neutrophilic leukemias, progressing myelofibrosis, and polycythemia vera, essential
thrombocythemia in transformation to acute leukemia or with progressive transfusion
requirements or pancytopenia.

- Chronic lymphocytic leukemia refractory to fludarabine treatment and with bulky
progressive disease or with thrombocytopenia (less than or equal to 100,000 /microl)
or anemia (less than or equal to 10g/dl) not due to recent chemotherapy.

- Non-Hodgkin's lymphoma including Mantle cell lymphoma relapsing or refractory to
standard of care treatments.

- Multiple myeloma, Waldenstroms macroglobulinemia, unresponsive or relapsed following
standard of care treatments.

- Ages 18-75 years inclusive.

- HLA identical (6/6) related donor.

- Ability to comprehend the investigational nature of the study and provide informed
consent.

Donor Criteria:

- Related HLA identical (6/6) with recipient.

- Weight greater than or equal to 18 kg.

- Age greater than or equal to 2 or less than or equal to 80 years old.

- For adults: Ability to comprehend the investigational nature of the study and provide
informed consent. For minors: Written informed consent from one parent or guardian
and informed assent: The process will be explained to the minor on a level of
complexity appropriate for their age and ability to comprehend.

EXCLUSION CRITERIA:

Recipient Criteria (any of the following):

- Malignant cells expressing a T cell phenotype (in particular T-ALL and T cell NHL).

- DLCO less than 65 percent predicted.

- Left ventricular ejection fraction less than 40 percent (evaluated by ECHO) or less
than 30 percent (evaluated by MUGA).

- AST/SGOT greater than 10 times ULN (CTCAE grade IV v3.0).

- Bilirubin greater than 5 times ULN (CTCAE grade IV v3.0).

- Creatinine greater than 4.5 times ULN (CTCAE grade IV v 3.0).

- HIV positive (Recipients who are positive for hepatitis B (HBV), hepatitis C (HCV) or
human T-cell lymphotropic virus (HTLV-1/II) are not excluded from participation).

- Positive pregnancy test for women of childbearing age.

- Prior allogeneic stem cell transplantation.

- Estimated probability of surviving less than three months.

- Major anticipated illness or organ failure incompatible with survival from
transplant.

- Severe psychiatric illness or mental deficiency sufficiently severe as to make
compliance with the transplant treatment unlikely and informed consent impossible.

Donor Criteria (any of the following):

- Pregnant or lactating.

- Unfit to receive filgrastim (G-CSF) and undergo apheresis (abnormal blood counts,
history of stroke, uncontrolled hypertension).

- Sickling hemoglobinopathies including HbSS, HbAS, HbSC.

- HIV positive Donors who are positive for hepatitis B (HBV), hepatitis C (HCV) or
human T-cell lymphotropic virus (HTLV-I/II) will be used at the discretion of the
investigator following counseling and approval from the recipient.

- Severe psychiatric illness or mental deficiency sufficiently severe as to make
compliance with the donation of stem cells unlikely and informed consent impossible.